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Abstract
Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase reported to be overexpressed in human leukemia. Though
much regarding the function of LTK remains unknown, it shares a high degree of similarity with anaplastic lymphoma kinase
(ALK), which is found mutated in human cancer. In order to determine if LTK has transforming potential, we created two LTK
mutants, F568L and R669Q, that correspond to two well-characterized activating mutations of ALK (F1174L and R1275Q).
LTK-F568L, but not wildtype LTK or LTK-R669Q, transformed hematopoietic cells to cytokine independence. LTK-F568L
exhibited a stronger ability to induce loss of contact inhibition and anchorage-independent growth of epithelial cells
compared to LTK-R669Q, while wildtype LTK was non-transforming in the same cells. Likewise, LTK-F568L induced greater
neurite outgrowth of PC12 cells than R669Q, while wildtype LTK could not. Correlating with transforming activity, LTK-F568L
displayed significantly enhanced tyrosine phosphorylation compared to wildtype LTK and LTK-R668Q and induced
activation of various signaling proteins including Shc, ERK and the JAK/STAT pathway. Expression of wildtype LTK or LTK-
R669Q generally led to weaker activation of signaling proteins than expression of LTK-F568L, or no activation at all. Thus,
mutating LTK at residue F568, and to a lesser extent at R669, activates the receptor tyrosine kinase, inducing cell signaling
that results in transforming properties. These studies suggest that aberrant activation of LTK may contribute to neoplastic
cell growth.
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Introduction
Receptor tyrosine kinases (RTKs) are cell signal transducers
which span the plasma membrane, binding ligands with their
extracellular domain [1]. Ligand-binding typically triggers recep-
tor dimerization, which in turn, causes the intracellular kinase
domain to become activated. Subsequently, activation of an
RTK’s kinase domain leads to autophosphorylation and the
phosphorylation of downstream targets that initiate signaling of
various pathways in the cell. Leukocyte tyrosine kinase (LTK) is a
RTK reported to be expressed in pre-B lymphocytes, B
lymphocytes, and other hematopoietic cells, as well as brain and
placenta [2–6]. It shares significant homology with fellow insulin-
receptor superfamily member anaplastic lymphoma kinase (ALK)
[7]. After the primary structure of LTK was partially determined
in 1988 [2], Krolewski et al. reported full-length LTK to be a
100 kDa glycosylated protein with demonstrable in vitro kinase
activity [8]. Although several splice variants of the protein exist,
full-length LTK is generated from the predominate cDNA isoform
that directs the synthesis of an 864 amino acid protein consisting of
an extracellular domain, transmembrane domain, a tyrosine
kinase domain, and a short carboxy terminus [4]. LTK contains
two NPXY motifs (which mediate the recruitment of adaptor
proteins for signal transduction) at Tyr485 and Tyr862, the former
of which is highly conserved among members of the insulin
receptor family [9]. Surprisingly, two decades after its cloning
much remains unknown regarding this protein’s function, largely
because a ligand for LTK has not been identified yet.
While the specifics of mammalian LTK function are unclear,
several studies have suggested that it plays an important role in
growth and development. In mice, aberrantly activated LTK
expressed from a transgene led to cardiac hypertrophy, cardio-
myocyte degeneration, as well as gene reprogramming [10]. In
zebrafish, LTK appears to be involved in fate specification of
neural crest cells [11]. Furthermore, experiments conducted by
Yamada et al. utilizing a chimeric LTK receptor suggest that LTK
kinase activity promotes neurite outgrowth via PI3K/AKT and
Ras/MAPK pathways [12]. Ueno et al.’s chimera work also
demonstrated that human LTK can activate the Ras pathway,
further implicating LTK in cell growth [9]. In pro-B cells
expressing an EGFR/LTK chimera, LTK has been shown to
associate with both IRS-1 (via Tyr485) and Shc (via Tyr862) and
that both tyrosines contribute to activation of the RAS pathway
and mitogenic signaling, while only Tyr485 contributes to anti-
apoptotic signaling [13]. LTK associates with PI3K (via Tyr753),
and this interaction is required for LTK to produce a survival
signal in hematopoietic cells [14]. In addition, LTK has been
reported to interact with other signaling proteins, including PLC-
gamma and cRaf, in a LTK kinase-dependent manner [15]. Given
LTK’s ability to signal through both growth promoting and anti-
apoptotic pathways, any dysregulation of the protein would be
expected to carry important consequences for disease develop-
ment, especially for neoplastic cell growth.
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which was found to be expressed in 10 of 18 leukemia samples,
including patient samples and cell lines, but not in 17 non-
leukemic neoplastic cells examined [5]. This suggests a possible
role for LTK in hematological malignancies. Further implicating
LTK dysregulation in leukemia, the LTK gene was found to be
overexpressed among 85 acute myeloid leukemia (AML) samples
[16]. Subsequent studies by the same research group revealed that
high expression of LTK in non-small cell lung cancer (NSCLC)
patients correlated with a 3-fold risk of metastasis in stage I/II
disease [17]. This suggests that LTK dysregulation may also have
important consequences for cancer progression in this tumor type.
Finally, Li et al. found that systemic lupus erythematosus (SLE)-
prone mice harbor a gain-of-function polymorphism (Gly746Glu)
in the LTK kinase domain near the PI3K binding motif [18]. The
authors postulate that such a mutation may contribute to the
aberrant activation of B cells seen in SLE. Taken together, just as
LTK signaling studies imply, these findings also suggest that
overexpressed and/or mutant LTK might contribute to disease.
Clearly a better understanding of LTK is needed in order to
ascertain its function in normal and disease states.
ALK is a protein highly related to LTK and together they are
members of their own subfamily within the insulin receptor
superfamily. Overall, the two proteins exhibit 54% identity of their
overlapping regions. ALK is thought to play a role in normal
nervous system development and function [7,19–21]. Like LTK,
ALK dysregulation has been implicated in carcinogenesis. Howev-
er, more progress has been made in understanding the role of ALK
in both normal and disease settings. One reason for this is that two
possible ALK ligands (midkine and pleiotrophin) have been
identified [22,23], although whether they are truly ALK ligands
remains controversial [24,25]. In addition, various mutant forms of
ALK have been reported in cancer. Full-length ALK was described
in 1997 as a large glycosylated transmembrane RTK [7,21]. The
extracellular region of ALK is much larger than that of LTK and
contains a number of domains that are not found in LTK—namely
two MAM (merpin, A5 protein and receptor protein tyrosine
phosphatase mu) domains and an LDLa (low-density lipoprotein
class A) motif. While function of the LDLa motif in ALK is
unknown, in the LDL receptor it is involved in ligand binding
[26,27]. MAM domains are thought to facilitate cell to cell
interaction/adhesion [28] and the ligand binding domain for
pleiotrophin and midkine fall within the first MAM domain [29].
However, both ALK and LTK share similar extracellular cysteine
residues, glycine-richdomains in the extracellular region nearest the
transmembrane domain, and NPXY motifsin their juxtamembrane
regions [7,28]. Importantly, the amino acid sequences of the ALK
and LTK tyrosine kinase domains are nearly 80% identical.
A truncated form of ALK was first described as part of a
transforming chimeric protein in non-Hodgkin’s lymphoma, in
which ALK sequences were found to be fused to sequences of the
nucleophosmin gene product (NPM) [30]. Since that time,
additional ALK fusion partners have been identified and
transforming versions of ALK as well as aberrant ALK expression
have been shown in cancers other than lymphoma including
adenocarcinomas of the lung [31,32], neuroblastomas [33–37],
breast [38] and esophageal cancers [39,40]. ALK is a frequent
target of mutation in familial neuroblastoma, where alterations in
the kinase domain lead to constitutive activation of the RTK and
phosphorylation of downstream targets, resulting in heightened
cell proliferation, invasion, and survival [34–37]. This is likely due
to the ability of ALK to activate the Ras/ERK, JAK/STAT, and
PI3K/AKT pathways. Among the ALK transforming mutations
reported in neuroblastomas, mutations at kinase domain residues
F1174 and R1275 are the most frequently reported [34,35], and
cells harboring these mutations have been shown to be sensitive to
small molecule inhibitors of ALK in vitro [35,41]. In fact, the ALK
inhibitor crizotinib was recently approved for use in certain
NSCLC patients [42,43] and a number of other ALK inhibitors
are currently in development or in clinical trials (reviewed in [44]).
Additionally, ALK dysregulation has been found to carry
histological and prognostic significance, underscoring the impor-
tance of these genetic changes in such cancers. For example,
presence of the fusion protein EML4-ALK has been found to
define histologically-distinct subsets of lung cancer [45], and ALK-
positive anaplastic large cell lymphomas (ALCL) appear to have a
better prognosis than ALK-negative ALCLs [46].
Though a substantial amount regarding the function of LTK
remains unknown, including how it may become dysregulated in a
disease state, the sequence similarity it shares with ALK may
provide important clues. As mutations in the ALK kinase domain
have been shown to be transforming, we hypothesized that this
may be the case for LTK as well. Moreover, the ALK F1174 and
R1275 mutational hotspots also correspond to known activating
mutations in EGFR and ERBB2 [47–49], suggesting that such
residues are key to regulating RTKs and thus likely LTK as well.
In order to determine if LTK has similar transforming potential
when mutated, we generated LTK proteins with mutations that
correspond to these two most common activating mutations of
ALK. Our goal in this study was to ascertain if altering these
residues would result in gain-of-function signaling and transform-
ing activity. Examination of the properties of such mutants is an
important first step to better elucidating the possible mechanisms
of LTK dysregulation in human malignancies. Our studies
demonstrate that the activating ALK-homologous mutations in
LTK differentially confer transforming activity on LTK.
Results
Generation and initial analyses of LTK F568L and R669Q
mutations
The ALK and LTK proteins are highly similar, sharing nearly
80% sequence identity in their kinase domains and 54% identity
over their overlapping region (Figure 1). The ALK kinase domain
mutations F1174L and R1275Q are two commonly reported
activating mutations, particularlyin familial neuroblastoma [34,35].
In order to determine if mutations in the kinase domain of LTK
possess a similar transforming potential as the known ALK
mutations, we generated mutations at the F568 and R669 residues
of LTK, which correspond to ALK F1174 and R1275, respectively
(Figure 1B). We utilized a pBABE-puro HA-tagged retroviral
expression vector to introduce mutant LTK into cells of interest.
Expression of wildtype and mutant versions of LTK in transfected
293T cells revealed similar levels of expression for each HA-tagged
LTK protein (Figure 2A). LTK protein migrated as a doublet, with
the major form being approximately 115 kDa, a slightly larger
molecular weight than has been reported previously [3]. We
hypothesized that glycosylation, which has beenreported previously
in some species of LTK [8], may account for the observed size
discrepancy. Therefore, we treated protein lysates from transfected
293T cells with PNGase F in order to remove protein glycosylation.
Indeed, treatment with PNGase F resulted in a reduction in the size
of the observed LTK protein, with the major band at ,115 kDa
shifting to an approximately 100 kDa band (Figure 2B), which is
closer to the 92 kDa predicted molecular weight of the protein
encoded by the cDNA that was expressed.
To determine if these LTK mutants induced activation of this RTK
we analyzed expressed LTK proteins for tyrosine phosphorylation in
Activation of LTK Transforming Properties
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LTK by immunoprecipitating HA-tagged LTK and immunoblotting
for phosphotyrosine. Our analyses revealed that LTK-F568L
demonstrated significantly enhanced tyrosine phosphorylation com-
pared to wildtype LTK, while the LTK-R669Q did not exhibit
e l e v a t e dt y r o s i n ep h o s p h o r y l a t i o n( F i g u r e2 C ) .W en e x te x a m i n e d
various signaling proteins, some of which are known to signal
downstream of LTK, for changes in phosphorylation status. Shc has
been reported to be a downstream signaling target of LTK [9], and in
fact, we detected a substantial increase in pShc (Y239/Y240) in the
cells expressing LTK-F568L when compared to cells expressing
wildtype LTK (Figure 2C). In contrast, cells expressing LTK-R669Q
displayed only a slight increase in pShc relative to cells expressing
wildtype LTK. Additional protein analysis of transfected 293T cells
also revealed that expression of LTK-F568L led to an increase in
pERK and a significant increase in pJAK1 and pJAK2 compared to
expression of either wildtype LTK or LTK-R669Q (Figure 2C).
Interestingly, expression of wildtype and LTK-R669Q did lead to
elevated pERK compared to empty vector, but this activation was less
than that observed with LTK-F568L. No enhancement of pAKT
(Figure 2c), pSTAT3, or pSTAT5 (data not shown) was detected in
this cell line.
LTK-F568L transforms BaF3 and 32D cells to cytokine
independence
BaF3 cells are a pro-B cell line and 32D cells are a myeloid
progenitor cell line, both of which are dependent on IL-3 for
viability and growth. These cell lines are used extensively to assess
Figure 1. Comparison of ALK and LTK structure and sequence. (A) Schematic of ALK and LTK. ALK and LTK are RTKs, each containing an
extracellular domain, a transmembrane domain (TMD, purple), and an intraceullar kinase domain (KD, green). ALK is a 1620 amino acid protein
containing two MAM domains (blue) and an LDLa motif in its extracellular region. LTK is composed of 864 amino acids and has a much smaller
extracellular domain that lacks these structures. The positions of the F1174L and R1275Q mutations of ALK and the corresponding mutations in LTK,
F568L and R669Q, are indicated. (B) Alignment of ALK and LTK kinase domains. ALK and LTK proteins share 80% sequence identity in their kinase
domains. Identical residues are indicated by an asterisk (*). Position of the FRL and RRQ residues of interest are shown in bold designated by arrows.
Boundaries of the kinase domains were determined using the Simple Modular Architecture Research Tool, http://smart.embl-heidelberg.de/and the
alignment was done using BLAST.
doi:10.1371/journal.pone.0031733.g001
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setting. ALK proteins containing either F1174L or R1275Q
mutations are able to transform BaF3 cells to IL-3-independence
[35]. To test if the F568L and R669Q mutants of LTK are
capable of mediating the transformation of hematopoietic cells,
we stably expressed wildtype, LTK-F568L, and LTK-R669Q in
both BaF3 and 32D cells. When these cells were cultured in the
absence of IL-3, cell viability and proliferation begin to decline
within 24 hours. Cultures of either parental BaF3 cells or BaF3
cells expressing wildtype LTK become 100% non-viable within
five to seven days, while wildtype LTK-expressing or parental
32D cells were all dead within three to five days (Figure 3A and
4A), as they are unable to proliferate in the absence of IL-3. In
comparison, BaF3 and 32D cells harboring the F568L mutation
became IL-3-independent (Figure 3A and 4A). BaF3 cells
expressing LTK-F568L reach IL-3-independence about five to
six days after IL-3 removal (Figure 3A), while the 32D cells
expressing LTK-F568L became IL-3-independent approximately
three to four days after cytokine removal (Figure 4A). However,
the R669Q mutant of LTK did not transform BaF3 or 32D cells
to IL-3-independence, as these cells responded to cytokine
withdrawal in a manner similar to cells expressing wildtype
LTK (Figure 3A and 4A). These data suggest that the F568L
mutation has a higher transforming potential than the R669Q
mutation in hematopoietic cells.
LTK mutants induce activation of cell signaling in
hematopoietic cells
We next investigated how expression of LTK proteins in
hematopoietic cells affected activation of various signaling
pathways. In order to eliminate signaling by IL-3, we cultured
cells for six hours in the absence of IL-3 before immunoblot
analysis. Similar to our results in 293T cells, LTK-F568L
demonstrated enhanced tyrosine phosphorylation compared to
wildtype LTK or LTK-R669Q in both BaF3 and 32D cells
(Figure 3B and 4B, lane 4, first two panels). We analyzed for
activation, via phosphorylation, various signaling proteins, includ-
ing Shc (at both Y239/Y240 and Y317), ERK, AKT, JAK1,
JAK2, STAT3, and STAT5. Comparing the data obtained from
the two different hematopoietic cell lines, LTK-F568L expression
lead to activation of Shc, ERK, STAT5, and AKT, while wildtype
LTK or LTK-R669Q either did not activate these proteins or did
not demonstrate consistent activation between the two cell lines
(Figure 3B and 4B). Importantly, as Shc is believed to be a direct
downstream target of LTK [13], it demonstrated high levels of
phosphorylation at tyrosines 239/240 and 317 only in cells that
expressed LTK-F568L. We also analyzed the phosphorylation
state of signaling proteins after cells expressing LTK-F568L
became IL-3 independent. The level of LTK-F568L protein
increased dramatically in cytokine-independent transformed cells
(Figure 3B and 4B, lane 5). This is likely due to a selective pressure
Figure 2. Expression of LTK constructs in 293T cells. (A) Relative protein expression of wildtype and mutant LTK constructs in 293T cells.
Lysates of 293T cells transiently expressing either HA-tagged vector control (v, lane 1), wildtype LTK (wt, lane 2), LTK-R669Q (RQ, lane 3), or LTK-F568L
(FL, lane 4) were immunoblotted with an anti-HA antibody as well as HSP90 as a loading control. (B) 293T cell lysates containing the LTK proteins
were treated with PNGase F (lanes 3, 5, and 7) or left untreated (lanes 2, 4, and 6) and immunoblotted with HA antibodies and HSP90 as a loading
control. (C) HA-tagged LTK proteins expressed in 293T cells were immunoprecipitated and immunoblotted with HA antibodies as well as anti-
phosphotyrosine (pTyr) antibodies (top). Antibodies that recognize the indicated proteins (Shc, pShC-Y239/Y240, ERK, pERK-T202/Y204, JAK1, pJAK1-
Y1022/Y1023, JAK2, pJAK2-Y1007/Y1008, AKT, and pAKT-S473) were used to immunoblot cell lysates of 293T cells expressing LTK proteins (bottom).
The phosphorylated form of the protein is designated with a ‘‘p’’ preceding the protein name.
doi:10.1371/journal.pone.0031733.g002
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provides a very potent anti-apoptotic as well as mitogenic signal.
Not surprisingly, this correlated with a further increase in
phosphorylation of Shc, ERK, and STAT5, and activation of
JAK1, JAK2, and STAT3 was also now readily evident (Figure 3B
and 4B, lane 5).
LTK mutants require JAK activity to transform
hematopoietic cells
The fact that cells transformed to IL-3 independence had
significant activation of the JAK/STAT pathway following
transformation to cytokine independence and not before, suggested
this pathway may play an important role in cellular transformation
in the context of LTK mutation in these cells. In order to assess
the role of the JAK family kinases in the transformation of
hematopoietic cell lines by LTK-F568L, we cultured LTK-F568L-
transformed BaF3cells with the pan-JAK inhibitor, JAK inhibitor I.
JAK inhibitor I induced a dose-dependent decrease in cell viability
(not shown) and growth in BaF3 cells transformed to cytokine
independence by LTK-F568L (Figure 5A). As JAK inhibitor I is
known to block phosphorylation of various STAT proteins and can
prevent ERK1/2 activation downstream of JAKs, we examined the
changes in the phosphorylation states of these proteins in BAF3 cells
treated with the JAK inhibitor (Figure 5B). This analysis revealed a
Figure 3. LTK-F568L transforms BaF3 cells to cytokine-independence. (A) BaF3 cells stably expressing LTK-F568L (red inverted triangles),
LTK-R669Q (green triangles), or wildtype LTK (blue squares) and parental control cells (black circles) were cultured in the absence of IL-3 at Day 0. The
total number of viable cells was determined at each timepoint by trypan blue exclusion. Similar results were obtained in three independent
experiments. The dashed line indicates cell numbers going below the detection of the hemacytometer towards zero. (B) Lysates from cells stably
expressing either HA-tagged vector control (v, lane 1), wildtype LTK (wt, lane 2), LTK-R669Q (RQ, lane 3), or LTK-F568L (FL, lane 4) were cultured in the
absence of IL-3 for six hours and immunoprecipitated with HA antibodies, followed by immunoblotting with HA and pTyr antibodies (first two blots).
The same lysates were immunoblotted with antibodies to the indicated cell signaling proteins (see Figure 2 legend plus pShc-Y317, STAT3, pSTAT3-
Y705, STAT5 and pSTAT5-Y694). Cell lysate from IL-3-independent LTK-F568L-expressing BaF3 cells was also analyzed (lane 5).
doi:10.1371/journal.pone.0031733.g003
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dramatic loss of phosphorylated ERK and STAT3, a surprising
reduction in Shc phosphorylation, yet no change in tyrosine
phosphorylation of LTK-F568L (Figure 5B).
Treatment of LTK-F568L Mutants with ALK Inhibitor
PF-2341066
In order to determine if the sequence similarities between ALK
and LTK could be exploited to target F568L-driven constitutive
activation of LTK, we cultured BaF3 cells transformed by LTK-
F568L with the cMET/ALK inhibitor PF-2341066 (Crizotinib).
In the presence of this inhibitor, cell viability decreased (not
shown) and cell proliferation was inhibited in a dose-dependent
manner (Figure 6A). As a control we treated BaF3 cells
transformed to cytokine independence by ALK-F1174L, with PF-
2341066 andobserved the expected inhibition of growth, only when
the cells were dependent on ALK for growth (i.e. no IL-3 in
medium) (Figure 6B). In contrast, when parental BAF3, wildtype
LTK,ornon-transformedLTK-F568L-expressingcells(allofwhich
are dependent on IL-3) were treated with the inhibitor, growth
and viability were unaffected (Figures 6C and D), suggesting PF-
2341066 is not non-specifically toxic to these cells. PF-2341066
treatment abolished tyrosine phosphorylation of LTK-F568L
(Figure 6E). We then examined the changes in the phosphorylation
status of signaling proteins in response to PF-2341066 and found a
markedreductioninthephosphorylationof Shc, STAT5, andAKT
proteins and a complete disappearance of phosphorylated ERK,
JAK1, JAK2, STAT3 proteins (Figure 6E).
Figure 4. LTK-F568L transforms 32D cells to cytokine-independence. (A) 32D cells stably expressing LTK-F568L (red inverted triangles), LTK-
R669Q (green triangles), or wildtype LTK (blue squares) and parental control cells (black circles) were cultured in the absence of IL-3 at Day 0. The total
number of viable cells was determined at each timepoint by trypan blue exclusion. Similar results were obtained in three independent experiments.
The dashed line indicates cell numbers going below the detection of the hemacytometer towards zero. (B) Lysates from cells stably expressing either
HA-tagged vector control (v, lane 1), wildtype LTK (wt, lane 2), LTK-R669Q (RQ, lane 3), or LTK-F568L (FL, lane 4) were cultured in the absence of IL-3
for six hours and immunoprecipitated with HA antibodies, followed by immunoblotting with HA and pTyr antibodies (first two blots). The same
lysates were immunoblotted with antibodies to the indicated cell signaling proteins (See Figure 3 legend). Cell lysate from IL-3-independent LTK-
F568L-expressing 32D cells was also analyzed (lane 5).
doi:10.1371/journal.pone.0031733.g004
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We next tested the signaling and transforming potential of
mutant LTK proteins in epithelial cells. We generated rat
intestinal epithelial (RIE) cells stably expressing wildtype LTK,
LTK-F568L, or LTK-R669Q. Similar expression was obtained
for each version of LTK (Figure 7A). We first analyzed these RIE
cells for changes in activation of signaling proteins in response to
LTK expression. While LTK proteins were equally expressed
LTK tyrosine phosphorylation was significantly enhanced in cells
expressing the F568L mutant of LTK, and a slight increase in
tyrosine phosphorylation was detectable on LTK-R669Q com-
pared to wildtype LTK (Figure 7A). Similarly, cells expressing
LTK-F568L also contained elevated levels of phosphorylated
versions of Shc, JAK1, STAT3, STAT5, and AKT compared to
cells expressing control vector, wildtype LTK, or LTK-R669Q
(Figure 7A). Interestingly, however, expression of wildtype LTK
and LTK-R669Q, in addition to LTK-F568L, upregulated the
phosphorylation of ERK, JAK1, and AKT compared to cells
expressing an empty vector control (Figure 7A).
In order to determine if the F568L and R669Q mutations of LTK
a r ea b l et ot r a n s f o r mt h e s ec e l l s ,w ec u l t u r e dR I Ec e l l sa n da l l o w e d
them to become confluent. Each of the stable lines became confluent
six days after plating. By Day 11, the LTK-F568L cells had acquired
a unique swirling morphology throughout the entirety of the plate as
cells grew on top of each other, indicating an ability to escape contact
inhibition (Figure 7B, lower panels). Interestingly, by Day 20,
transformed colonies appeared in the LTK-R669Q plates. This
morphology was different than LTK-F568L cells, with the LTK-
R669Q-expressing cells forming compact dense clusters of cells
(Figure 7B, lower panels). Wildtype LTK-expressing cells exhibited
no sign of escaping contact inhibition of growth. The ability of LTK-
F568L to induce contact inhibition is perhaps more evident following
crystal violet staining, where cultures of these cells exhibited dense
staining throughout the plate, compared to the monolayer of cells
expressing wildtype LTK and the distinct foci of the cells expressing
LTK-R669Q (Figure 7B, top panel). These results suggest that LTK-
F568L, and to a lesser extent LTK-R669Q, are able to confer the
ability of cells to escape normal contact inhibitory growth controls.
Figure 5. Transformation of BaF3 cells by LTK-F568L requires JAK family kinase activity. (A) BaF3 cells transformed to cytokine
independence by LTK-F568L were cultured in the presence of 0.5 mM (green squares) or 1 mM (blue triangles) JAK Inhibitor I (JI) or 0.1% DMSO (red
circles) on Day 0. The total number of viable cells was determined by trypan blue exclusion. Dashed lines indicate viable cell counts going below the
limit of detection of the hemacytometer towards zero. Similar results were obtained in two independent experiments. (B) IL-3-independent LTK-
F568L BaF3 cells were treated with 1 mM (lane 2) JI or DMSO (lane 1) for three hours and immunoblotted for the indicated proteins (See Figure 3
legend). Phosphotyrosine (pTyr) on LTK-F568L was detected by immunoblotting following immunoprecipitating LTK-F568L with HA antibodies.
doi:10.1371/journal.pone.0031733.g005
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independence by LTK-F568L were left untreated (0.1% DMSO, black circles) or cultured in the presence of 0.5 mM (blue squares), 1 mM (green
triangles), or 2 mM (red inverted triangles) of the cMET/ALK inhibitor PF2341066 (PF) on Day 0. The total number of viable cells for each treatment was
determined daily by trypan blue exclusion. (B) IL-3-dependent (+IL-3) BaF3 cells harboring ALK-F1174L were cultured without (black circles) or with
(blue squares) 0.5 mM PF2341066. BaF3 cells transformed to IL-3-independence by ALK-F1174L were cultured without (green triangles) or with (red
inverted triangles) 0.5 mM PF2341066. The total number of viable cells for each treatment was determined daily by trypan blue exclusion. (C) Parental
BaF3 cells were cultured without (black circles) or with (blue squares) 0.5 mM PF2341066. BaF3 cells expressing wildtype LTK were cultured without
(green triangles) or with (red inverted triangles) 0.5 mM PF2341066. The total number of viable cells for each treatment was determined daily by
trypan blue exclusion. (D) IL-3-dependent BaF3 cells expressing LTK-F568L were cultured without (black inverted triangles) or with (blue circles)
0.5 mM PF2341066. BaF3 cells transformed to IL-3 independence by LTK-F568L were cultured without (green squares) or with (red diamonds) 0.5 mM
PF2341066. The total number of viable cells for each treatment was determined daily by trypan blue exclusion. In (A) thru (D), the dashed lines
indicate viable cell counts going below the limit of detection of the hemacytometer towards zero. For each of the experiments in (A) thru (D), similar
results were obtained in each independent (at least two) experiment performed. (E) IL-3-independent BaF3 LTK-F568L-expressing cells were treated
with 1 mM PF-2341066 (lane 2) or DMSO (lane 1) for 2 hours. Cell lysates were collected and immunoprecipitated and/or immunoblotted, as indicated
(see Figure 3 legend).
doi:10.1371/journal.pone.0031733.g006
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RIE cells containing either wildtype LTK, LTK-F568L, or LTK-
R669Q were plated in soft agar to assess the ability of LTK
mutants to induce anchorage independent growth. LTK-F568L
and LTK-R669Q-expressing cells formed visible colonies five days
after plating, while cells expressing wildtype LTK did not form
colonies. Colonies of cells expressing the LTK-F568L mutant
continued to grow in size, becoming much larger than the R669Q
colonies by 14 days after plating (Figure 8A). Overall, LTK-
F568L showed a stronger transforming phenotype than LTK-
R669Q in this assay, forming six times more colonies than LTK-
R669Q-expressing cells (Figure 8B). Thus, while cells expressing
LTK-F568L readily formed colonies in soft agar, LTK-R669Q
showed a weak transforming phenotype in this assay. While
not as strong as LTK-F568L, the transforming ability of LTK-
R669Q was still distinct from expression of wildtype LTK, which
Figure 7. LTK-F568L and LTK-R669Q transform epithelial cells. (A) Cell lysates from RIE cells stably expressing either empty vector (v, lane 1),
wildtype LTK (wt, lane 2), LTK-R669Q (RQ, lane 3), or LTK-F568L (FL, lane 4) were analyzed by immunoprecipitation and immunoblotting, as indicated
(see Figure 3 legend). (B) RIE cells stably expressing either wildtype LTK (wt), LTK-F568L (F568L), or LTK-R669Q (R669Q) were plated and reached
confluency after six days. Cells were cultured further and growth was grossly assessed for the loss of contact inhibition. Cells expressing wildtype LTK
did not grow beyond confluency, continuing to exhibit contact inhibition. However, cells expressing LTK-F568L continued to proliferate, forming
swirling patterns of cells growing on top of the monolayer. Cells expressing LTK-R669Q formed distinct secondary morphological structures as these
cells formed compact clusters of cells that grew on top of the monolayer of cells. Representative photographs of cells are shown: plates were stained
with crystal violet (top row) after photographs were taken at 106 with a digital camera (middle) and 506 with a Zeiss Automated Fluorescent
Microscope using AxioVision (bottom row). Results shown are representative of similar findings of three independent experiments.
doi:10.1371/journal.pone.0031733.g007
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ALK inhibitor PF-2341066 inhibited anchorage independent
growth of both LTK-F568L and LTK-R669Q-expressing cells
(Figure 8A–8B). A pan-JAK inhibitor also inhibited anchorage
independent growth of cells expressing mutant LTK proteins
(Figure 8C).
Figure 8. LTK-F568L and LTK-R669Q induce anchorage independent growth, which is inhibited by PF-2341066. (A) RIE cells stably
expressing either wildtype LTK, LTK-F568L, or LTK-R669Q were plated in soft agar and assessed for anchorage-independent growth. LTK-F568L-
expressing cells formed large colonies in soft agar while LTK-R669Q-expressing cells formed fewer colonies which were also significantly smaller.
Including PF2341066 (PF) in the medium inhibited anchorage independent growth in soft agar. Photographs show representative fields after two
weeks of culture. Results shown for are representative of similar findings of three independent experiments. (B) Quantitation of anchorage
independent growth of RIE cells expressing wildtype LTK, LTK-F568L, and LTK-R669Q fourteen days after plating in the absence (blue bars) and
presence of 0.5 mM (green bars) or 1.0 mM (black bars) PF2341066 (PF). (C) Quantitation of anchorage independent growth of RIE cells expressing
wildtype LTK, LTK-F568L, and LTK-R669Q fourteen days after plating in the absence (blue bars) and presence of 0.5 mM (yellow bars) or 1 mM JAK
Inhibitor (red bars). Data represents average colonies per field view per plate. Error bars represent standard error of the mean from two or three
independent experiments performed in duplicate.
doi:10.1371/journal.pone.0031733.g008
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neurite outgrowth in PC12 cells
LTK has been reported to mediate neurite outgrowth when
expressed as a chimera with CSF1R [12]. Upon stimulation with
CSF1, such chimeras autophosphorylate CSF1R/LTK, leading to
the formation of neurites from undifferentiated PC12 cells [12]. As
a final analysis for deregulated LTK activity we expressed an
empty vector control, wildtype LTK, LTK-F568L, or LTK-
R669Q transiently in PC12 cells. LTK proteins were expressed
with GFP and GFP-positive cells were assessed for differentiation
and neurite outgrowth over a ten day period. Both LTK-F568L
and LTK-R669Q were able to induce neurite outgrowth, as
measured by the presence of cells with extended neurites longer
than their bodies (Figure 9A). In contrast, vector-transfected cells
as well as cells transfected with wildtype LTK did not differentiate
(Figure 9A). When quantified, we found that 6.7% of GFP-positive
LTK-F568L transfected cells and 2.7% of GFP-positive LTK-
R669Q cells had neurite outgrowth by Day 3, while almost no
(0.25%) wildtype LTK-expressing cells exhibited neurite out-
growth (Figure 9B). In comparison, when PC12 cells are treated
with nerve growth factor (NGF), a strong inducer of differentia-
tion, we observed that 26% of GFP-positive cells displayed neurite
outgrowth by Day 3 (data not shown). We followed the GFP-
positive cells for 10 days and found that the percentage of GFP-
Figure 9. LTK-F568L and LTK-R669Q induce PC12 cell neurite outgrowth. (A) PC12 cells were co-transfected with GFP and either vector,
wildtype LTK, LTK-R669Q, or LTK-F568L. Cells were observed for neurite outgrowth. PC12 cells treated with 1 uM NGF are shown as control for neurite
extensions. Photographs of representative cells were taken four days after transfection. Arrows indicate neurite outgrowth. Two photographs for
both LTK-F568L and LTK-R669Q are shown. (B) GFP-positive PC12 cells transiently expressing either vector control (v, red bars), wildtype LTK (wt,
black bars), LTK-R669Q (RQ, blue bars), or LTK-F568L (FL, green bars) were counted daily for ten days and the percent exhibiting neurite outgrowth is
shown. GFP was strongly expressed through Day 7, after which expression began to diminish and became undetectable after Day 10. Data shown is
the average of two independent experiments done in duplicate with error bars representing standard error of mean. At least 500 GFP-positive cells
were assessed per plate.
doi:10.1371/journal.pone.0031733.g009
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which point the GFP signal began to fade. Seven days after
transfection, 18.2% of GFP-positive LTK-F568L transfected cells
and 6.9% of GFP-positive LTK-R669Q transfected cells exhibited
neurite outgrowth, while no detectable neurite outgrowth was
observed in wildtype LTK-expressing cells (Figure 9B).
Discussion
Aberrant activation of various RTKs has long been associated
with tumorigenesis. Point mutations in kinase domains of RTKs
such as EGFR, HER2, MET, KIT, and FLT3 (among others)
have been implicated as driver mutations in various cancers such
as lung, breast, renal, liver, intestinal, and leukemia (reviewed in
[50]). Such mutations tend to result in constitutive activation of the
kinase domain, which ultimately contributes to escape from
normal cellular growth controls. The gene for LTK, an RTK
highly similar to ALK, is located within a chromosomal region
implicated as a major breakpoint cluster domain in mouse models
of radiation-induced AML [51]. Further evidence for the
involvement of LTK in malignancies emerged when the gene
was found to be overexpressed in a subset of AML patients [16]
and overexpression of LTK was found to confer an increased risk
of metastasis in NSCLCs [17]. Despite this knowledge, uncovering
the specifics of LTK function has been hampered by the fact that
the ligand(s) for this receptor is not known. Studies using chimeras
constructed from the extracellular portion of the EGF receptor
with the transmembrane and cytoplasmic domains of LTK have
provided evidence that activation of the LTK kinase domain leads
to signaling through the Ras pathway via Grb2 and the adaptor
protein Shc [9]. Along with cell growth, LTK appears to be
involved in anti-apoptotic signaling [13,14]. Thus, disruption of
normal LTK function may carry important consequences for
neoplastic cell growth. For these reasons, we undertook the current
study to investigate likely ways in which LTK could become
constitutively activated and to observe the implications of such
changes.
We utilized the high degree of conservation of kinase domain
residues between LTK and ALK to inform our choice of
candidate residues most likely to confer transforming properties
when mutated. Two ALK residues in particular—F1174 and
R1275—result in constitutive kinase domain activation when
mutated in neuroblastomas [34,35]. As with many kinase domain
mutations implicated in cancer, the F1174 and R1275 mutations
in ALK leads to phosphorylation of downstream targets and result
in heightened cell proliferation, invasion, and survival [34–37].
We report here for the first time the consequences of the
expression of LTK proteins containing mutations at the analogous
sites to these ALK residues. Our analyses revealed that, in many
ways, LTK-F568L and LTK-R669Q behave similarly to the
F1174L and R1275Q mutants of ALK. Overall, the F568L
mutation was a stronger activator of LTK signaling than the
R669Q mutation (Figures 2, 3, 4, and 7). While R669Q mutant
cells showed evidence of being able to escape normal growth
controls (losing contact inhibition and exhibiting anchorage
independent growth), this activity was considerably weaker than
that of LTK-F568L (Figures 7 and 8). Additionally, while the
F568L mutant of LTK was able to transform hematopoietic cells
to IL-3 independence, LTK-R669Q was not (Figures 3 and 4).
Such findings are consistent with research of the corresponding
ALK mutations, wherein ALK-F1174L is considered more highly
transforming than the R1275Q mutation [35].
The F568L mutation of LTK results in constitutive tyrosine
phosphorylation of the receptor and expression of this LTK
mutant leads to phosphorylation of several key signaling proteins
that appear to act downstream of LTK (Figures 2, 3, 4, and 7).
LTK has three phosphotyrosine sites that have previously been
reported to be key in mitogenic and survival signaling: Y485,
Y753, and Y862 [13,14]. Tyrosine 753 of LTK is located within a
kinase domain YXXM motif and appears to be involved in
survival signaling via PI3K activation [14]. Tyrosine 485 of LTK
is part of a NPXY motif located within the juxtamembrane
domain which is highly conserved among the insulin receptor
family (and which corresponds to Y1096 of ALK) [9]. Once
phosphorylated, both Y485 and Y862 have been reported to
associate with downstream signaling molecules, with Y862 being
the major site of association with Shc resulting in the recruitment
of Grb2/Sos and Ras activation [9,14]. We found evidence of this
LTK/Shc relationship, as numerous cell types expressing LTK-
F568L revealed a marked increase in the phosphorylation of Shc
tyrosines 239, 240, and 317 (known to be GRB2-binding sites)
[52,53], compared to cells expressing wildtype LTK (Figures 2, 3,
4, and 7). We also found evidence that activated LTK leads
to phosphorylation of various proteins within the JAK/STAT
pathway, including JAK1, JAK2, STAT3, and STAT5 (Figures 2,
3, 4, and 7), and that survival of hematopoietic cells transformed to
cytokine independence by LTK-F568L expression requires JAK
signaling. When hematopoietic cells transformed by LTK-F568L
were treated with a pan JAK inhibitor, we found a decrease in or
complete loss of the phosphorylated form of JAK1 and JAK2 as
well as their downstream targets STAT3 and STAT5, as would be
expected (Figure 5). Tyrosine phosphorylation of LTK remained
unchanged during JAK inhibitor treatment. However, we
observed a decrease in phosphorylated Shc and a complete
disappearance of phosphorylated ERK in these cells. These data
suggest, but do not prove, that activated JAK signaling contributes
to Shc tyrosine phosphorylation and ERK activation downstream
of activated LTK.
STAT3 activation and AKT phosphorylation have been
reported following ALK-F1174L expression [34,35]. Consistent
with this, we also found evidence of STAT3 activation following
the transformation of two hematopoietic cell lines by LTK-F568L
as well as upon expression of this LTK mutant in epithelial cells
(Figure 3, 4, and 7). When we examined mutant LTK cells for
AKT activation, we found that in 32D cells only LTK-F568L
expression increased AKT phosphorylation (Figure 4). In BAF3
cells the expression of LTK-F568L resulted in a slight increase in
phosphorylated AKT (compared to vector control), while
expression of LTK-R669Q exhibited a more marked increase in
phosphorylated AKT in these cells (Figure 3). The opposite was
true in epithelial cells, where LTK-F568L activated AKT to a
greater extent than LTK-R669Q did (Figure 7). However, 293T
cells failed to show any changes in AKT phosphorylation with
expression of either mutation (Figure 2). Expression of ALK-
R1275Q has been shown to lead to ERK1/2 activation [35], while
results are conflicting as to whether ALK-F1174L does [34,54] or
does not [35] result in similar activation of ERK 1/2. In our
experiments, we observed that LTK-F568L is as good and in some
cell types a stronger activator of ERK than LTK-R669Q. Such
findings suggest, not surprisingly, that cell type may play a role in
determining which downstream signaling pathways become
activated when a LTK mutation confers gain of function signaling
activity.
In addition to holding important implications for hematopoietic
cells, we found that mutant LTK confers important changes in
cells of other types. In epithelial cells, both mutations were able to
confer the ability to escape normal growth controls, including
exhibiting anchorage independent growth (Figure 8). Additionally,
Activation of LTK Transforming Properties
PLoS ONE | www.plosone.org 12 February 2012 | Volume 7 | Issue 2 | e31733our findings reveal that the F568L mutation of LTK is sufficient to
induce differentiation of PC12 cells as measured by neuronal
outgrowth (Figure 9). This provides additional evidence that LTK-
F568L is a constitutively activated receptor tyrosine kinase. These
observations are consistent with previous work utilizing a CSF1R/
LTK chimera in PC12 cells, which suggests that LTK activation
can signal through pathways resulting in neuronal differentiation
[12]. Importantly, expression of LTK-R669Q also induced
differentiation of PC12 cells, albeit to a significantly less extent
than LTK-F568L (Figure 9). Nonetheless, this indicates LTK-
R669Q is capable of inducing differentiation signals in PC12
cells, suggesting this mutant LTK does exhibit a level of increased
signaling. In support of this, we observed that BAF3 cells
expressing LTK-R669Q show an increase in phosphorylation of
certain signaling proteins such as STAT5 and AKT, compared to
wildtype LTK (Figure 3). Taken together, our data suggest that
while LTK-R669Q does not readily exhibit potent transforming
and cell signaling-inducing activity, expression of this LTK mutant
does suggest it is a weakly activating mutation.
It remains to be determined whether or not activating LTK
mutations are present in human cancer. Our work suggests that
certain LTK mutations may have the ability to contribute to
neoplastic cell growth, as has been demonstrated for ALK, whose
kinase domain is nearly 80% identical to the kinase domain of
LTK (Figure 1). Mutations of the corresponding residues of
ALK have proved important in understanding the pathology of
neuroblastomas that carry these genetic changes [34–37].
Moreover, the F1174 mutation of ALK occurs in a region of the
kinase domain that is often mutated in EGFR and HER2 [55].
The R1275Q mutation of ALK is correspondingly adjacent to the
most common lung cancer-associated mutation (L858R) in EGFR
[55]. The similarity in the location of these ALK mutations, and
thus the corresponding LTK mutations investigated in our study,
to other activating tyrosine kinase domain mutations in cancer
underscores the important consequences of mutation of this region
of tyrosine kinases. Mutationally activated ALK is found in
NSCLC and, interestingly, examination of LTK expression in
patients with NSCLC revealed that patients with LTK overex-
pression had a three-fold higher risk of metastasis [17]. While our
work shows that mutationally activated LTK can induce
transformation of various cell types including epithelial cells,
overexpression of wildtype LTK does not. However, overexpres-
sion of wildtype LTK does lead to activation of some downstream
signaling proteins, such as ERK, in certain cell types (Figure 2, 3,
and 7). Thus, it is possible that overexpression of LTK may
contribute in some manner to enhanced signaling of distinct
intracellular pathways, which if not significant on its own, may
sensitize cells to additional genomic insults. Also, constitutively
activated ALK is known to carry prognostic value in cancers such
as lung cancer [45] and ALCL [46,56], thus providing further
evidence that mutations in LTK that induce constitutive signaling
may provide clinically important information.
Importantly, we found that cells transformed by LTK-F568L
are susceptible to the ALK inhibitor PF-2341066 (Crizotinib)
(Figure 6 and 8). While little is known about the normal role of
LTK, it is worth noting that treatment of cells with PF-2341066 to
target mutationally-activated ALK may produce off-target effects
through inhibition of LTK. Our work suggests that the similarities
between ALK and LTK may be exploited for treatment options if
LTK is found to have a role in driving certain cohorts of cancer
patients. Having a potential therapeutic agent available makes the
identification of potential activating LTK mutations in cancer all
the more intriguing. While the size of the patient population with
cancers containing activating LTK mutations, if any, is not yet
known, advances in genomic sequencing, which will provide data
for the personalization of therapeutic treatments for patients,
makes the identification of such a population significant. This is
especially true if these cancers can be effectively targeted by drugs
already being used in patients. While further research is needed to
elucidate the role of LTK in human cancer, the potential for
improved prognosis is significant if LTK-driven neoplasms can be
identified and met with targeted treatments. Future whole genome
sequencing approaches will rely heavily on studies such as
ours presented here to determine the significance of identified
mutations.
In conclusion, we demonstrate that expression of LTK
mutations homologous to known activating mutations of ALK
leads to elevated activation and cell signaling compared to
wildtype LTK. LTK-F568L is a stronger transforming mutation
than LTK-R669Q in multiple cell types. Signaling and trans-
forming activity of mutated LTK proteins are evident in cells of
hematopoietic and epithelial origin, as well as in cells used to
model neuronal differentiation, suggesting aberrant activation of
LTK may play a role in neoplastic disease of multiple cell types.
Materials and Methods
Cell Culture and Retrovirus Production
293T [57] and RIE [58] cells were maintained in DMEM
supplemented with 10% fetal bovine serum (FBS). BaF3 [57] and
32D [59] cells were grown in RPMI medium 1640 supplemented
with 10% FBS and 5% WEHI-3B conditioned medium (as a
source of IL-3). PC12 (ATCC: CRL-1721) cells were maintained
in RPMI-1640 supplemented with 10% horse serum and 5%
FBS. Ecotropic retrovirus was made in 293T cells using the
pVPack system (Stratagene). Stable cell lines were generated by
retroviral infection followed by selection with 1 mg/mL of
puromycin as described previously [57].
Construction of LTK Expression Plasmids
Wildtype LTK was amplified by PCR (PrimeSTAR DNA
p o l y m e r a s e ,T a k a r aB i o ,I n c . )f r o mc D N Ag e n e r a t e df r o mr e v e r s e
transcribed (Thermoscript Reverse Transcriptase, Invitrogen)
mRNA from the leukemic cells of a patient with acute myeloid
leukemia. The cDNA for LTK was cloned into pBabepuro-CHA
[57]. The F568L and R669Q mutations of LTK were generated by
PCR-mediated site-directed mutagenesis using PrimeSTAR DNA
polymerase (Takara Bio, Inc.). Mutagenesis primers were as follows:
59-CCC-TCA-TCA-TCA-GCA-AGT-TAC-GCC-ATC-AGA-AC-
A-T and 59-ATG-TGA-TGG-CGT-ACC-TTG-CTG-ATG-ATG-
AGG-G for the F568L mutation; and 59-CTT-TGG-GAT-GGC-
ACA-AGA-TAT-CTA-CCG-GG and 59-CCC-GGT-AGA-TAT-
CTT-GTG-CCA-TCC-CAA-AG for the R669Q mutation. The
sequence of all cDNAs amplified by PCR was confirmed by DNA
sequencing.
PNGase Treatment
293T cells were lysed in lysis buffer (as described below, see
Immunoblot Analysis) and protein concentration was determined
by a BCA protein assay kit (Thermo Scientific). Fifty micrograms
of protein were treated with PNGAse F (New England Biolabs),
per manufacturer’s instructions. Equal amounts of protein were
analyzed by immunoblotting.
Cell Growth Analysis
To assay 32D and BaF3 cell response to IL-3 deprivation, cells
were washed twice with RPMI-1640 supplemented with 10% FBS.
Cells were then plated at a concentration of 4610
5 per ml in
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viability were monitored over time by trypan blue exclusion.
Immunoblot Analysis
Cells were washed in PBS and lysed in lysis buffer, composed of
25 mM Tris (pH 7.4), 150 mM NaCl, 25 mM NaF, 1% Triton X-
100, 1 mM sodium vanadate, 2 mM sodium pyrophosphate,
10 mg/ml leupeptin, 2 mg/ml aprotinin, and 1 mM PMSF.
Protein concentrations were determined with a BCA protein
assay kit (Thermo Scientific), and equal amounts of protein were
analyzed by SDS/PAGE. Primary antibodies used in this study
include: phospho-(p)STAT5(Y694) (611964) (BD Biosciences);
AKT (sc-8312), HSP90a/b (sc-7947), pJAK2(Y1007/Y1008) (sc-
16566-R), Shc (sc-1695), STAT3 (sc-483), STAT5 (sc-835),
ERK1/2 (sc-93) (Santa Cruz Biotechnology); HA (MMS-101R)
(Covance); JAK1 (3344), JAK2 (3230), pAKT(S473) (4051),
pERK(T202/Y204) (4370), pShc(Y239/240) (2434), pShc (Y317)
(2431), and pSTAT3(Y705) (9138) (Cell Signaling); pJAK1
(Y1022/Y1023) (44-422G) (Invitrogen); and ptyrosine 4G10
(05-321X) (Millipore). Primary antibodies were detected with
corresponding horse radish peroxidase conjugated secondary
antibodies (Thermo Scientific). Immunoblots were developed
using ECL Western Blotting Substrate (Thermo Scientific).
Immunoprecipitation
Approximately 8610
6 Baf3 and 32D cells were washed in PBS
before being lysed in lysis buffer. Protein concentrations were
determined with a BCA protein assay kit (Thermo Scientific).
500 mg of protein were combined with 10 ml HA-probe(Y-11) (sc-
805) (Santa Cruz Biotechnology), 20 ml Protein A beads (Thermo
Scientific), and brought to a final volume of 1 mL in lysis buffer.
The solution was placed on a rotator overnight at 4uC. The
immunoprecipitation reactions were spun down at max speed for
30 seconds at 4uC, and washed with 1 mL fresh lysis buffer. This
wash was repeated three more times. The IP reactions were then
resuspended in 25 ml sample buffer and boiled for 5 min at 95uC,
before being analyzed by immunoblotting.
JAK Inhibitor I Studies
BaF3 and 32D cells were plated at 2610
5 cells per ml in growth
medium containing 0.1% DMSO, 0.5 mM, or 1 mM JAK inhibitor
I (EMD Biosciences/Calbiochem). After addition of the inhibitor,
cell growth and viability were determined over time by trypan blue
exclusion. For soft agar assays, RIE cells were plated in soft agar
with 0.5 mMo r1mM of JAK inhibitor I.
ALK Inhibitor Studies
BaF3 cells transformed by LTK-F568L were plated at 1.25610
5
cells per ml in RPMI-1640 supplemented with 10% FBS and
either 0.1% DMSO, 0.5 mM, 1 mM, or 2 mM cMET/ALK
inhibitor PF-2341066 (Crizotinib) (ChemieTek). After addition of
the inhibitor, cell growth and viability were determined over time
by trypan blue exclusion. For soft agar assays, RIE cells were
plated in soft agar with 0.5 mMo r1mM PF-2341066 (Crizotinib).
Detection of Loss of Contact Inhibition
RIE cells stably expressing wildtype LTK, LTK-F568L, or
LTK-R669Q were plated in 10 cm dishes at a density of 1610
6
cells per plate. Growth medium was replaced every other day
during the entire experiment and cells were allowed to become
confluent. Once confluency was reached, cells were monitored for
the next three weeks for evidence of loss of contact inhibited cell
growth and photographed. Plates were also fixed with 10%
methanol/10% acetic acid and stained with 0.4% crystal violet for
3 minutes, before being rinsed with dH20, dried, and scanned.
Soft Agar Assay
1610
5 RIE cells stably expressing wildtype LTK, LTK-F568L,
or LTK- R669Q were plated in duplicate in DMEM/10% FBS
containing 0.4% agar on top of DMEM/10% FBS containing
0.6% agar. In order to assess the relative number of colonies
formed, the 60 cm plate was broken down into quadrants. A field
view was selected at random within each quadrant, all colonies
within that field view were counted, and the resulting counts
averaged. For drug treatment during soft agar assays, cells were
plated with 0.5 mMo r1mM PF-2341066 (Crizotinib) or JAK
inhibitor I.
PC12 Cell Transfection
PC12 cells transiently co-expressing GFP and either wildtype
LTK, LTK-F568L, or LTK- R669Q or vector control DNA were
generated by nucleofection. Two million PC12 cells were
resuspended in 100 mL Bio Ingenio Electroporation Solution
(Mirus) along with 2 mg DNA of interest and 0.5 mg GFP
expression plasmid. The suspension was transfected in duplicate
according to the manufacturer’s PC12 specific protocol (Lonza)
and the suspension was transferred to 2 mL of RPMI 1640/10%
horse serum/5% FBS and plated in 12-well dishes. The
percentage of GFP-positive cells that exhibited neurite outgrowth
was recorded each day for ten days.
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